Genfit reports strong cash position to fund operations through 2028

Genfit, a French biopharmaceutical company specializing in rare liver diseases, has reported its financial results for the first half of 2026. The company holds 113.8 million euros in cash and cash equivalents as of June 30, 2026, a position expected to fund its operations and investments beyond the end of 2028.

Revenue for the period reached 21.1 million euros, with 21.0 million euros derived from royalties through an agreement with Ipsen. Notably, Ipsen has doubled its peak annual global sales target for Iqirvo, a treatment for primary biliary cholangitis, to 1 billion euros.

In other developments, Genfit announced that its NASHnext test has obtained Medicare coverage in the United States. Additionally, the company is advancing its clinical pipeline, including Phase 2 trials for acute liver failure and ongoing development for cholangiocarcinoma.